According to a new report by Polaris Market Research, the global immunotherapy drugs market was valued at USD 327.74 billion in 2025 and is projected to reach USD 1,152.03 billion by 2034, expanding at a CAGR of 15.0% over the forecast period. Growth is underpinned by rising cancer and autoimmune disease prevalence, expanding CAR-T and checkpoint-inhibitor pipelines, and accelerating regulatory approvals across key end-use industries.

What Is Driving Immunotherapy Drugs Market Growth?

Demand is climbing as the growing global burden of cancer converges with advancements in targeted biologic therapies. Manufacturers and health systems are prioritizing precision immuno-oncology platforms, pushing immunotherapy drug adoption across North America, Europe, and Asia Pacific. Polaris analysts note that rising R&D investment and favorable regulatory policy position the industry for sustained double-digit growth through 2034, with cancer treatment emerging as the largest revenue contributor and combination-therapy approaches posting the fastest incremental gains.

Key Trends Shaping the Immunotherapy Drugs Industry

Increasing Advancements in Research and Development

Continual innovation in CAR-T cell therapy and immune checkpoint inhibitors is expanding the range of treatable conditions. The FDA's March 2024 approval of Bristol Myers Squibb's Breyanzi as the first CAR-T therapy for relapsed or refractory chronic lymphocytic leukemia illustrates how technology advancement is broadening the competitive landscape.

Growing Adoption of Combination Therapies

Pairing immunotherapy with chemotherapy or targeted therapy is improving treatment efficacy and overcoming resistance mechanisms in harder-to-treat cancers. The FDA's April 2024 approval of the N-803 and BCG combination for bladder cancer, based on a UCLA-led clinical trial, reflects a broader regulatory landscape shift toward multi-modal regimens.

Expansion of Antibody Engineering and Personalized Vaccines

Advances in bispecific antibodies, antibody-drug conjugates, and personalized cancer vaccines are improving precision and reducing off-target toxicity. Research such as the University of Pennsylvania's 2024 work on switchable bispecific antibodies signals a widening market outlook centered on personalized oncology treatment.

Market Segmentation: Breaking Down the Immunotherapy Drugs Market

Polaris segments the immunotherapy drugs market by type, application, route of administration, end user, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Type

The antibody drugs segment held the largest share in 2025, given proven efficacy across cancers and autoimmune diseases and the precision offered by monoclonal antibodies. Inhibitor drugs, interferons and interleukins, vaccines, and other modalities round out the remaining segment basis, with antibody engineering continuing to widen the segment's therapeutic reach.

By Application

The cancer segment dominated the market in 2025 and is expected to retain its lead through the forecast period, driven by high unmet medical need and strong clinical results across cancer types such as melanoma and lung cancer. Autoimmune and inflammatory diseases, hematology, osteology, and neurology represent the remaining application segments tracked in the report.

By Route of Administration

On a route-of-administration basis, the market spans intravenous, subcutaneous, oral, and other delivery formats, with intravenous administration continuing to anchor hospital-based immunotherapy protocols while subcutaneous and oral formulations expand access in outpatient settings.

By End User

Among end users — hospitals, long-term care facilities, and others — hospitals remain the primary setting for immunotherapy administration given the infusion infrastructure and monitoring these therapies require, while long-term care facilities are seeing rising utilization as maintenance regimens extend.

Regional Outlook: Where Is the Immunotherapy Drugs Market Growing Fastest?

North America held more than 40% of the global market in 2025, led by high cancer prevalence and a robust healthcare infrastructure that supports rapid approval and adoption of new therapies. Asia Pacific is anticipated to grow at the fastest rate, driven by expanding healthcare infrastructure, a high incidence of cancer, and a growing pipeline of clinical trials, supported by regional collaboration platforms such as the Asia Pacific Vaccine and Immunotherapy Congress.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/immunotherapy-drugs-market 

Competitive Landscape: Leading Immunotherapy Drugs Companies

Key players profiled in the report include AbbVie Inc., Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, and Merck & Co., among others, who are focusing on R&D investment, licensing deals, and regulatory approvals to strengthen market position across the cancer and autoimmune disease segments outlined above. Recent moves include Bayer's March 2025 global licensing agreement with Puhe BioPharma for an experimental oral cancer therapy, and the FDA's June 2024 approval of Merck's KEYTRUDA combination regimen for endometrial carcinoma, both aimed at deepening share in oncology.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the immunotherapy drugs opportunity, this report benchmarks market share, segment-level data, and forecast figures — by type, application, route of administration, end user, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking combination therapies as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Computer Numerical Control Machine Market

Live Package Tracking Market

Internet of Behaviors Market

Protein A, G, and L Resins Market

Live Package Tracking Market

Automotive Tire Market

Digital Therapeutics Market

Navigating the Seas of Success: Exploring the Subscription Billing Management Market

Healthcare Staffing And Scheduling Software Market